Name: Nanopharmaceuticals Market Size and Trends
Creator: Coherent Market Insights
License: https://www.coherentmarketinsights.com/privacy-policy
Keywords: Nanopharmaceuticals Market, Nanopharmaceuticals Market Report, Nanopharmaceuticals Industry Report, Nanopharmaceuticals Market Size, Nanopharmaceuticals Market Share, Nanopharmaceuticals Market Analysis, Nanopharmaceuticals Market Growth, Nanopharmaceuticals Market Trends, Nanopharmaceuticals Market Overview, Nanopharmaceuticals Market Forecast

Nanopharmaceuticals Market, by Carrier Type (Liposomes, Polymer, Nanocrystals, Inorganic, Protein, and Others), by Application (Oncology, Neurology, Anti-inflammatory, Anti-infective, Cardiovascular, and Others), by End User (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global industry Insights and Forecast till 2026

Published In : Feb 2019

Code : CMI2485

Pages :170

Formats :

Excel and PDF

Industry : Pharmaceutical

Nanopharmaceuticals MarketSize and Trends

The global nanopharmaceuticals market size was valued at US$ 28,434.3 million in 2017, and is expected to exhibit a CAGR of 22.1 % over the forecast period (2018–2026).

Figure 1. Global Nanopharmaceuticals Market Value (US$ Mn), by Region, 2017

Source: Coherent Market Insights Analysis (2018)

Figure 2. Global Nanopharmaceuticals Market Share (%), by Carrier Type, 2018 and 2026

Source: Coherent Market Insights Analysis (2018)

Increasing prevalence of cancer and neurological diseases is expected to propel growth of the global nanopharmaceuticals market

Nanopharmaceuticals are used in various conditions such as cancer, neurological disorders, and other diseases. Moreover, high prevalence of cancer globally, is expected to drive the market growth. According to World Health Organization (WHO), September 2018 factsheet, around 9.6 million deaths occurred due to cancer, and the disease was second leading cause of death, globally.

Increasing incidences of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease is expected to propel growth of the global nanopharmaceuticals market over the forecast period. According to the World Alzheimer Report 2015, around 46 million people were diagnosed with dementia worldwide in 2015, which was estimated to increase to around 131.5 million by 2050.